A Phase 2 interventional study of Setmelanotide and Placebo in Prader-Willi Syndrome, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 5 sites in United States. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-27.
Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.
Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 19th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2015, is one of 17 in phase 2, and was the 20th registered.
144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.
Browse Prader-Willi Syndrome studies →9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 13–17
ConSynance Therapeutics · Sites in United States
Ages 13–50
Grace Kim · Sites in United States
Ages 18–26
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Healthy volunteers
Harmony Biosciences Management, Inc. · Sites in United States, Australia, Belgium and 10 more countries
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.
This study: 16 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 23 · Phase 3 16 · Phase 4 3
First in 1999; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is above the median of 30 across 100 interventional studies indexed under Prader-Willi Syndrome.
Median enrollment 23 across the 58 interventional studies, 200 across the 11 observational. Of the 51 that completed or were terminated, 21 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 69 have an industry lead sponsor. The 10 most frequent:
Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
Rhythm Pharmaceuticals, Inc. has 3 studies filed under Prader-Willi Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Prader-Willi Syndrome with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06366464Phase 3Harmony Biosciences Management, Inc.A Study of Pitolisant in Patients With Prader-Willi Syndrome | 2027-04 |
| NCT06144645Phase 3Foundation for Prader-Willi ResearchA Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS | 2027-04-01 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06239116Rhythm Pharmaceuticals, Inc.A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment | 2027-05-07 |
| NCT07348601ConSynance TherapeuticsA Study of CSTI-500 in Patients With Prader-Willi Syndrome | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Prader-Willi Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the effects of a once daily subcutaneous injectable formulation of setmelanotide in obese participants with Prader-Willi syndrome on tolerability, weight loss, and hyperphagia-related behavior. The study drug (setmelanotide and placebo) was administered in a blinded fashion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If a participant has diagnosis of type 2 diabetes, following criteria must be met:
Vital signs must be within the following ranges and stable.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received setmelanotide 0.5 milligrams (mg) once daily as a subcutaneous injection from Day 15 to Day 41 (4-week, double-blind randomized treatment period) and Day 42 to Day 55 (2-week, randomized withdrawal period).
Drug: Setmelanotide
Participants received setmelanotide 1.5 once daily as a subcutaneous injection from Day 15 to Day 41 (4-week, double-blind randomized treatment period), Day 42 to Day 55 (2-week, randomized withdrawal period), and Day 56 to Day 69 (optional 2-week, open-label extension period).
Drug: Setmelanotide
Participants received setmelanotide 2.5 once daily as a subcutaneous injection from Day 15 to Day 41 (4-week, double-blind randomized treatment period), Day 42 to Day 55 (2-week, randomized withdrawal period), and Day 56 to Day 69 (optional 2-week, open-label extension period).
Drug: Setmelanotide
Participants received placebo matched to setmelanotide once daily as a subcutaneous injection from Day 1 to Day 14 (2-week, single-blind run-in period), Day 15 to Day 41 (4-week, double-blind randomized treatment period), and Day 42 to Day 55 (2-week, randomized withdrawal period).
Drug: Placebo
subcutaneous injection
Also known as: RM-493
Subcutaneous injection
Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) - Period 2
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE is considered to be treatment-emergent if the onset date/time is during or after administration of double-blind study drug or, in the event that onset time precedes double-blind study drug administration, the AE increases in severity during or after administration of double-blind study drug; in either case through 1-week after the last treatment dose. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent disability/incapacity; * Was a congenital anomaly/birth defect
Time frame: Days 15 to 41
Number of Participants Who Experienced a TEAE - Period 3
An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE is considered to be treatment-emergent if the onset date/time is during or after administration of double-blind study drug or, in the event that onset time precedes double-blind study drug administration, the AE increases in severity during or after administration of double-blind study drug; in either case through 1-week after the last treatment dose. An SAE was any untoward medical occurrence that, at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent disability/incapacity; * Was a congenital anomaly/birth defect
Time frame: Days 42 to 55
Number of Participants Who Experienced a TEAE - Period 4
An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE is considered to be treatment-emergent if the onset date/time is during or after administration of double-blind study drug or, in the event that onset time precedes double-blind study drug administration, the AE increases in severity during or after administration of double-blind study drug; in either case through 1-week after the last treatment dose. An SAE was any untoward medical occurrence that, at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent disability/incapacity; * Was a congenital anomaly/birth defect
Time frame: Days 56 to 69
Mean Body Weight - Period 2
Time frame: Baseline (Day 15)
Percent Change From Baseline in Body Weight - Period 2
Time frame: Baseline (Day 15) and Day 42
Overall Score of Prader-Willi Syndrome (PWS) Hyperphagia Questionnaire - Period 2
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia).
Time frame: Baseline (Day 15)
Percent Change From Baseline in Overall Score of Prader-Willi Syndrome (PWS) Hyperphagia Questionnaire - Period 2
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia). Percent change from baseline in overall score of PWS hyperphagia questionnaire is presented.
Time frame: Baseline (Day 15) and Day 42
Percent Change From Baseline in Hyperphagic Drive Score of PWS Hyperphagia Questionnaire - Period 2
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Hyperphagic drive score assesses the persistence in asking for food based on 4 items. All 4 items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Possible scores for hyperphagic drive range from a minimum score of 4 (no hyperphagic drive) to a maximum score of 20 (greater hyperphagic drive). Percent change from baseline in hyperphagic drive score of PWS hyperphagia questionnaire is presented.
Time frame: Baseline (Day 15) and Day 42
Percent Change From Baseline in Hyperphagic Behaviors Score of PWS Hyperphagia Questionnaire - Period 2
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Hyperphagic behavior factor score assesses food seeking behaviors based on 4 items. All 4 items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Possible scores for hyperphagic behaviors range from a minimum score of 4 (no hyperphagic behavior) to a maximum score of 20 (greater hyperphagic behavior). Percent change from baseline in hyperphagic behaviors score of PWS hyperphagia questionnaire is presented.
Time frame: Baseline (Day 15) and Day 42
Percent Change From Baseline in Hyperphagic Severity Score of PWS Hyperphagia Questionnaire - Period 2
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Hyperphagic severity factor score assesses the severity of hyperphagia based on 2 items. Both items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Possible scores for hyperphagic severity range from a minimum score of 2 (no hyperphagic severity) to a maximum score of 10 (greater hyperphagic severity). Percent change from baseline in hyperphagic severity score of PWS hyperphagia questionnaire is presented.
Time frame: Baseline (Day 15) and Day 42
Percent Change From Baseline in Overall Score of PWS Hyperphagia Questionnaire - Period 3
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia). Percent change from baseline in overall score of PWS hyperphagia questionnaire is presented.
Time frame: Baseline (Day 42) and Day 56
Percent Change From Baseline in Overall Score of PWS Hyperphagia Questionnaire - Period 4
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia). Percent change from baseline in overall score of PWS hyperphagia questionnaire is presented.
Time frame: Baseline (Day 56) and Day 70
Mean Setmelanotide Trough Concentrations
The average of setmelanotide trough concentrations values for both timepoints (5 minutes predose on Day 42 and Day 70) is presented.
Time frame: 5 minutes predose on Day 42 and Day 70
Maximum Drug Concentration (Cmax) of Setmelanotide During a 24-Hour Steady-State Interval
Maximum drug concentration determined directly from individual concentration-time data.
Time frame: Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing
Time to the Maximum Drug Concentration (Tmax) of Setmelanotide During a 24-Hour Steady-State Interval
Maximum drug concentration determined directly from individual concentration-time data.
Time frame: Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing
Area Under the Drug Concentration-Time Curve From Time-Zero to 24 Hours Postdose (AUC24h) of Setmelanotide During a 24-Hour Steady-State Interval
Time frame: Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing
Volume of Distribution (Vd) of Setmelanotide During a 24-Hour Steady-State Interval
Volume of distribution calculated as Dose/The observed terminal rate constant\*AUC24h.
Time frame: Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing
Total Clearance (CL) of Setmelanotide During a 24-Hour Steady-State Interval
Clearance after extravascular administration; calculated as Dose/AUC24h.
Time frame: Starting on any day from Day 63 through 69, a 24-hour PK profile obtained; blood samples were collected at 0 (within 5 minutes predose), 1, 2, 4, 6, 7, 8, 9, 10, 12, and 24 hours after dosing
Change From Baseline in Body Weight - Period 2
Time frame: Baseline (Day 15) and Day 42
Percent Change From Baseline in Body Weight - Period 3
Time frame: Baseline (Day 42) and Day 56
Percent Change From Baseline in Body Weight - Period 4
Time frame: Baseline (Day 56) and Day 70
Percent Change From Baseline in Body Weight for Continuous Active and Continuous Placebo Treatments - Period 2 and 3
Time frame: Baseline (Day 15), Day 42, Day 56
Percent Change From Baseline in Body Fat Measured Using Dual x-Ray Absorptiometry (DEXA) - Period 2
Total body fat was assessed by DEXA scan.
Time frame: Baseline (Day 15) and Day 42
Number of Participants With Clinically Significant Percent Change From Baseline in Body Fat Measured Using DEXA - Period 4
Total body fat was assessed by DEXA scan. Number of participants with clinically significant percent change from baseline in body fat were judged by investigator.
Time frame: Baseline (Day 56) and Day 70
Percent Change From Baseline in Body Mass Measured Using DEXA - Period 2
Total body mass was assessed by DEXA scan.
Time frame: Baseline (Day 15) and Day 42
Number of Participants With Clinically Significant Percent Change From Baseline in Body Mass Measured Using DEXA - Period 4
Total body mass was assessed by DEXA scan. Number of participants with clinically significant percent change from baseline in body mass were judged by investigator.
Time frame: Baseline (Day 56) and Day 70
| Milestone | Setmelanotide 0.5 mg | Setmelanotide 1.5 mg | Setmelanotide 2.5 mg | Placebo |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 40 |
| Completed | 0 | 0 | 0 | 40 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Setmelanotide 0.5 mg | Setmelanotide 1.5 mg | Setmelanotide 2.5 mg | Placebo |
|---|---|---|---|---|
| Started | 4 | 13 | 8 | 15 |
| Completed | 4 | 13 | 7 | 15 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by participant and investigator decision | 0 | 0 | 1 | 0 |
| Milestone | Setmelanotide 0.5 mg | Setmelanotide 1.5 mg | Setmelanotide 2.5 mg | Placebo |
|---|---|---|---|---|
| Started | 3 | 10 | 5 | 20 |
| Completed | 3 | 10 | 5 | 20 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Setmelanotide 0.5 mg | Setmelanotide 1.5 mg | Setmelanotide 2.5 mg | Placebo |
|---|---|---|---|---|
| Started | 0 | 22 | 16 | 1 |
| Completed | 0 | 22 | 16 | 1 |
| Not completed | 0 | 0 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE is considered to be treatment-emergent if the onset date/time is during or after administration of double-blind study drug or, in the event that onset time precedes double-blind study drug administration, the AE increases in severity during or after administration of double-blind study drug; in either case through 1-week after the last treatment dose. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent disability/incapacity; * Was a congenital anomaly/birth defect
| Participants | Setmelanotide 0.5 mg (Double-blind Randomized Treatment) | Setmelanotide 1.5 mg (Double-blind Randomized Treatment) | Setmelanotide 2.5 mg (Double-blind Randomized Treatment) | Placebo (Double-blind Randomized Treatment) |
|---|---|---|---|---|
| Participants with at least 1 TEAE | 4 | 11 | 6 | 11 |
| Participants with at least 1 SAE | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE is considered to be treatment-emergent if the onset date/time is during or after administration of double-blind study drug or, in the event that onset time precedes double-blind study drug administration, the AE increases in severity during or after administration of double-blind study drug; in either case through 1-week after the last treatment dose. An SAE was any untoward medical occurrence that, at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent disability/incapacity; * Was a congenital anomaly/birth defect
| Participants | Setmelanotide 0.5 mg (Randomized Withdrawal Period) | Setmelanotide 1.5 mg (Randomized Withdrawal Period) | Setmelanotide 2.5 mg (Randomized Withdrawal Period) | Placebo (Randomized Withdrawal Period) |
|---|---|---|---|---|
| Participants with at least 1 TEAE | 3 | 7 | 4 | 11 |
| Participants with at least 1 SAE | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE is considered to be treatment-emergent if the onset date/time is during or after administration of double-blind study drug or, in the event that onset time precedes double-blind study drug administration, the AE increases in severity during or after administration of double-blind study drug; in either case through 1-week after the last treatment dose. An SAE was any untoward medical occurrence that, at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent disability/incapacity; * Was a congenital anomaly/birth defect
| Participants | Setmelanotide 1.5 mg (Open-Label Extension) | Setmelanotide 2.5 mg (Open-Label Extension) | Placebo (Open-Label Extension) |
|---|---|---|---|
| Participants with at least 1 TEAE | 17 | 12 | 0 |
| Participants with at least 1 SAE | 0 | 0 | 0 |
| Kilograms (kg) | Setmelanotide 0.5 mg (Double-blind Randomized Treatment) | Setmelanotide 1.5 mg (Double-blind Randomized Treatment) | Setmelanotide 2.5 mg (Double-blind Randomized Treatment) | Placebo (Double-blind Randomized Treatment) |
|---|---|---|---|---|
| Mean Body Weight - Period 2 | 94.3 ± 16.84 | 92.7 ± 5.50 | 101.6 ± 5.35 | 102.2 ± 9.16 |
| percent change | Setmelanotide 0.5 mg (Double-blind Randomized Treatment) | Setmelanotide 1.5 mg (Double-blind Randomized Treatment) | Setmelanotide 2.5 mg (Double-blind Randomized Treatment) | Placebo (Double-blind Randomized Treatment) |
|---|---|---|---|---|
| Percent Change From Baseline in Body Weight - Period 2 | -0.7 (-3.1 to 1.8) | -0.8 (-2.2 to 0.6) | 0.4 (-1.2 to 2.0) | -0.4 (-1.8 to 0.9) |
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia).
| units on a scale | Setmelanotide 0.5 mg (Double-blind Randomized Treatment) | Setmelanotide 1.5 mg (Double-blind Randomized Treatment) | Setmelanotide 2.5 mg (Double-blind Randomized Treatment) | Placebo (Double-blind Randomized Treatment) |
|---|---|---|---|---|
| Overall Score of Prader-Willi Syndrome (PWS) Hyperphagia Questionnaire - Period 2 | 31.0 ± 2.86 | 21.2 ± 2.28 | 20.2 ± 2.79 | 18.7 ± 2.33 |
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia). Percent change from baseline in overall score of PWS hyperphagia questionnaire is presented.
| percent change | Setmelanotide 0.5 mg (Double-blind Randomized Treatment) | Setmelanotide 1.5 mg (Double-blind Randomized Treatment) | Setmelanotide 2.5 mg (Double-blind Randomized Treatment) | Placebo (Double-blind Randomized Treatment) |
|---|---|---|---|---|
| Percent Change From Baseline in Overall Score of Prader-Willi Syndrome (PWS) Hyperphagia Questionnaire - Period 2 | 20.2 (-8.7 to 49.1) | -5.2 (-21.3 to 10.9) | -5.0 (-23.7 to 13.6) | -1.3 (-16.9 to 14.3) |
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Hyperphagic drive score assesses the persistence in asking for food based on 4 items. All 4 items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Possible scores for hyperphagic drive range from a minimum score of 4 (no hyperphagic drive) to a maximum score of 20 (greater hyperphagic drive). Percent change from baseline in hyperphagic drive score of PWS hyperphagia questionnaire is presented.
| percent change | Setmelanotide 0.5 mg (Double-blind Randomized Treatment) | Setmelanotide 1.5 mg (Double-blind Randomized Treatment) | Setmelanotide 2.5 mg (Double-blind Randomized Treatment) | Placebo (Double-blind Randomized Treatment) |
|---|---|---|---|---|
| Percent Change From Baseline in Hyperphagic Drive Score of PWS Hyperphagia Questionnaire - Period 2 | 27.2 (-8.9 to 63.3) | -3.6 (-24.1 to 16.9) | -6.8 (-30.5 to 16.8) | 6.6 (-13.2 to 26.4) |
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Hyperphagic behavior factor score assesses food seeking behaviors based on 4 items. All 4 items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Possible scores for hyperphagic behaviors range from a minimum score of 4 (no hyperphagic behavior) to a maximum score of 20 (greater hyperphagic behavior). Percent change from baseline in hyperphagic behaviors score of PWS hyperphagia questionnaire is presented.
| percent change | Setmelanotide 0.5 mg (Double-blind Randomized Treatment) | Setmelanotide 1.5 mg (Double-blind Randomized Treatment) | Setmelanotide 2.5 mg (Double-blind Randomized Treatment) | Placebo (Double-blind Randomized Treatment) |
|---|---|---|---|---|
| Percent Change From Baseline in Hyperphagic Behaviors Score of PWS Hyperphagia Questionnaire - Period 2 | 19.1 (-19.3 to 57.5) | -1.7 (-22.3 to 18.9) | -3.0 (-26.8 to 20.8) | -0.4 (-20.4 to 19.6) |
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Hyperphagic severity factor score assesses the severity of hyperphagia based on 2 items. Both items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Possible scores for hyperphagic severity range from a minimum score of 2 (no hyperphagic severity) to a maximum score of 10 (greater hyperphagic severity). Percent change from baseline in hyperphagic severity score of PWS hyperphagia questionnaire is presented.
| percent change | Setmelanotide 0.5 mg (Double-blind Randomized Treatment) | Setmelanotide 1.5 mg (Double-blind Randomized Treatment) | Setmelanotide 2.5 mg (Double-blind Randomized Treatment) | Placebo (Double-blind Randomized Treatment) |
|---|---|---|---|---|
| Percent Change From Baseline in Hyperphagic Severity Score of PWS Hyperphagia Questionnaire - Period 2 | 33.2 (-4.4 to 70.9) | -0.7 (-22.1 to 20.6) | 5.5 (-19.1 to 30.2) | -16.7 (-37.3 to 3.9) |
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia). Percent change from baseline in overall score of PWS hyperphagia questionnaire is presented.
| percent change | Setmelanotide 0.5 mg (Randomized Withdrawal Period) | Setmelanotide 1.5 mg (Randomized Withdrawal Period) | Setmelanotide 2.5 mg (Randomized Withdrawal Period) | Placebo (Randomized Withdrawal Period) |
|---|---|---|---|---|
| Percent Change From Baseline in Overall Score of PWS Hyperphagia Questionnaire - Period 3 | 35.0 (-2.9 to 72.9) | -1.8 (-18.4 to 14.7) | 3.4 (-20.1 to 26.9) | 2.3 (-9.6 to 14.2) |
The hyperphagia questionnaire is a 10-item instrument designed to measure food-related preoccupations and problems in PWS, as well as the severity of these concerns. Three factors identified from this questionnaire are: Hyperphagic Drive, Hyperphagic Behaviors, and Hyperphagic Severity. Items are rated by care providers on a 5-point scale (1=not a problem to 5=a severe and/or frequent problem). Raw scores for each factor were used in data analyses, and the 3 domains were summed for an overall summary index of hyperphagia. Possible scores on the questionnaire range from a minimum score of 10 (no hyperphagia) to a maximum score of 50 (greater hyperphagia). Percent change from baseline in overall score of PWS hyperphagia questionnaire is presented.
| percent change | Setmelanotide 1.5 mg (Open-Label Extension) | Setmelanotide 2.5 mg (Open-Label Extension) |
|---|---|---|
| Percent Change From Baseline in Overall Score of PWS Hyperphagia Questionnaire - Period 4 | -0.9 ± 23.21 | -0.4 ± 29.94 |
The average of setmelanotide trough concentrations values for both timepoints (5 minutes predose on Day 42 and Day 70) is presented.
| nanograms per milliliter (ng/mL) | Setmelanotide 0.5 mg | Setmelanotide 1.5 mg | Setmelanotide 2.5 mg |
|---|---|---|---|
| Mean Setmelanotide Trough Concentrations | 0.790 ± 0.336 | 2.59 ± 1.51 | 5.63 ± 4.19 |
Maximum drug concentration determined directly from individual concentration-time data.
| ng/mL | Setmelanotide 2.5 mg (Open-Label Extension) |
|---|---|
| Maximum Drug Concentration (Cmax) of Setmelanotide During a 24-Hour Steady-State Interval | 39.1 ± 12.2 |
Maximum drug concentration determined directly from individual concentration-time data.
| hours (hr) | Setmelanotide 2.5 mg (Open-Label Extension) |
|---|---|
| Time to the Maximum Drug Concentration (Tmax) of Setmelanotide During a 24-Hour Steady-State Interval | 6.00 (5.95 to 10.15) |
| hr*ng/mL | Setmelanotide 2.5 mg (Open-Label Extension) |
|---|---|
| Area Under the Drug Concentration-Time Curve From Time-Zero to 24 Hours Postdose (AUC24h) of Setmelanotide During a 24-Hour Steady-State Interval | 569.4 ± 190.6 |
Volume of distribution calculated as Dose/The observed terminal rate constant\*AUC24h.
| Liters (L) | Setmelanotide 2.5 mg (Open-Label Extension) |
|---|---|
| Volume of Distribution (Vd) of Setmelanotide During a 24-Hour Steady-State Interval | 52.8 ± 10.0 |
Clearance after extravascular administration; calculated as Dose/AUC24h.
| L/hr | Setmelanotide 2.5 mg (Open-Label Extension) |
|---|---|
| Total Clearance (CL) of Setmelanotide During a 24-Hour Steady-State Interval | 4.77 ± 1.49 |
| kg | Setmelanotide 0.5 mg (Double-blind Randomized Treatment) | Setmelanotide 1.5 mg (Double-blind Randomized Treatment) | Setmelanotide 2.5 mg (Double-blind Randomized Treatment) | Placebo (Double-blind Randomized Treatment) |
|---|---|---|---|---|
| Change From Baseline in Body Weight - Period 2 | -0.6 (-3.1 to 1.8) | -0.8 (-2.2 to 0.7) | 0.3 (-1.4 to 1.9) | -0.4 (-1.8 to 1.0) |
| percent change | Setmelanotide 0.5 mg (Randomized Withdrawal Period) | Setmelanotide 1.5 mg (Randomized Withdrawal Period) | Setmelanotide 2.5 mg (Randomized Withdrawal Period) | Placebo (Randomized Withdrawal Period) |
|---|---|---|---|---|
| Percent Change From Baseline in Body Weight - Period 3 | 1.3 (-0.3 to 2.9) | 0.0 (-0.9 to 0.9) | 0.0 (-1.3 to 1.3) | 0.2 (-0.4 to 0.9) |
| percent change | Setmelanotide 1.5 mg (Open-Label Extension) | Setmelanotide 2.5 mg (Open-Label Extension) |
|---|---|---|
| Percent Change From Baseline in Body Weight - Period 4 | -0.0 ± 0.90 | 0.0 ± 2.70 |
| percent change | Setmelanotide 0.5 mg (Double-blind Randomized Treatment, Then Randomized Withdrawal Period) | Setmelanotide 1.5 mg (Double-blind Randomized Treatment, Then Randomized Withdrawal Period) | Setmelanotide 2.5 mg (Double-blind Randomized Treatment, Then Randomized Withdrawal Period) | Placebo (Double-blind Randomized Treatment), Then Placebo (Randomized Withdrawal Period) |
|---|---|---|---|---|
| Percent change at Day 42 | -0.7 (-5.3 to 3.9) | -0.5 (-3.1 to 2.2) | 0.7 (-2.6 to 4.0) | -0.7 (-3.2 to 1.7) |
| Percent change at Day 56 | 0.2 (-4.8 to 5.3) | -0.4 (-3.3 to 2.6) | 0.9 (-2.7 to 4.4) | -1.0 (-3.8 to 1.7) |
Total body fat was assessed by DEXA scan.
| percent change | Setmelanotide 0.5 mg (Double-blind Randomized Treatment) | Setmelanotide 1.5 mg (Double-blind Randomized Treatment) | Setmelanotide 2.5 mg (Double-blind Randomized Treatment) | Placebo (Double-blind Randomized Treatment) |
|---|---|---|---|---|
| Percent Change From Baseline in Body Fat Measured Using Dual x-Ray Absorptiometry (DEXA) - Period 2 | -0.6 (-3.4 to 2.1) | -1.1 (-2.7 to 0.5) | -0.7 (-2.6 to 1.3) | -1.1 (-2.7 to 0.4) |
Total body fat was assessed by DEXA scan. Number of participants with clinically significant percent change from baseline in body fat were judged by investigator.
| Participants | Setmelanotide 1.5 mg (Open-Label Extension) | Setmelanotide 2.5 mg (Open-Label Extension) |
|---|---|---|
| Number of Participants With Clinically Significant Percent Change From Baseline in Body Fat Measured Using DEXA - Period 4 | 0 | 0 |
Total body mass was assessed by DEXA scan.
| percent change | Setmelanotide 0.5 mg (Double-blind Randomized Treatment) | Setmelanotide 1.5 mg (Double-blind Randomized Treatment) | Setmelanotide 2.5 mg (Double-blind Randomized Treatment) | Placebo (Double-blind Randomized Treatment) |
|---|---|---|---|---|
| Percent Change From Baseline in Body Mass Measured Using DEXA - Period 2 | -0.2 (-2.3 to 1.9) | -1.1 (-2.3 to 0.2) | -0.3 (-1.8 to 1.2) | -0.9 (-2.1 to 0.3) |
Total body mass was assessed by DEXA scan. Number of participants with clinically significant percent change from baseline in body mass were judged by investigator.
| Participants | Setmelanotide 1.5 mg (Open-Label Extension) | Setmelanotide 2.5 mg (Open-Label Extension) |
|---|---|---|
| Number of Participants With Clinically Significant Percent Change From Baseline in Body Mass Measured Using DEXA - Period 4 | 0 | 0 |
Collected over Day 15 to Day 69. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Setmelanotide 0.5 mg (Double-blind Randomized Treatment) | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Setmelanotide 1.5 mg (Double-blind Randomized Treatment) | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| Setmelanotide 2.5 mg (Double-blind Randomized Treatment) | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Placebo (Double-blind Randomized Treatment) | 0/15 (0%) | 0/15 (0%) | 11/15 (73.3%) |
| Setmelanotide 0.5 mg (Randomized Withdrawal Period) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Setmelanotide 1.5 mg (Randomized Withdrawal Period) | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Setmelanotide 2.5 mg (Randomized Withdrawal Period) | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Placebo (Randomized Withdrawal Period) | 0/20 (0%) | 0/20 (0%) | 11/20 (55%) |
| Setmelanotide 1.5 mg (Open-Label Extension) | 0/22 (0%) | 0/22 (0%) | 17/22 (77.3%) |
| Setmelanotide 2.5 mg (Open-Label Extension) | 0/16 (0%) | 0/16 (0%) | 12/16 (75%) |
| Placebo (Open-Label Extension) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Event | Setmelanotide 0.5 mg (Double-blind Randomized Treatment) | Setmelanotide 1.5 mg (Double-blind Randomized Treatment) | Setmelanotide 2.5 mg (Double-blind Randomized Treatment) | Placebo (Double-blind Randomized Treatment) | Setmelanotide 0.5 mg (Randomized Withdrawal Period) | Setmelanotide 1.5 mg (Randomized Withdrawal Period) | Setmelanotide 2.5 mg (Randomized Withdrawal Period) | Placebo (Randomized Withdrawal Period) | Setmelanotide 1.5 mg (Open-Label Extension) | Setmelanotide 2.5 mg (Open-Label Extension) | Placebo (Open-Label Extension) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 3/4 | 5/13 | 4/8 | 6/15 | 2/3 | 4/10 | 4/5 | 4/20 | 8/22 | 6/16 | 0/1 |
| Injection site bruisingGeneral disorders | 3/4 | 1/13 | 1/8 | 3/15 | 1/3 | 0/10 | 0/5 | 1/20 | 5/22 | 0/16 | 0/1 |
| Injection site indurationGeneral disorders | 2/4 | 4/13 | 2/8 | 3/15 | 2/3 | 2/10 | 0/5 | 4/20 | 6/22 | 6/16 | 0/1 |
| HeadacheNervous system disorders | 2/4 | 1/13 | 0/8 | 0/15 | 0/3 | 0/10 | 0/5 | 1/20 | 2/22 | 1/16 | 0/1 |
| Injection site oedemaGeneral disorders | 0/4 | 2/13 | 1/8 | 2/15 | 1/3 | 2/10 | 0/5 | 0/20 | 6/22 | 2/16 | 0/1 |
| Injection site pruritusGeneral disorders | 1/4 | 3/13 | 0/8 | 1/15 | 1/3 | 1/10 | 0/5 | 0/20 | 2/22 | 1/16 | 0/1 |
| Injection site swellingGeneral disorders | 1/4 | 0/13 | 0/8 | 0/15 | 0/3 | 0/10 | 0/5 | 0/20 | 0/22 | 0/16 | 0/1 |
| Skin discolourationSkin and subcutaneous tissue disorders | 1/4 | 2/13 | 0/8 | 0/15 | 0/3 | 0/10 | 0/5 | 0/20 | 0/22 | 0/16 | 0/1 |
| Injection site painGeneral disorders | 0/4 | 1/13 | 1/8 | 1/15 | 0/3 | 0/10 | 0/5 | 0/20 | 2/22 | 0/16 | 0/1 |
| Injection site discolourationGeneral disorders | 0/4 | 1/13 | 0/8 | 0/15 | 0/3 | 0/10 | 0/5 | 0/20 | 0/22 | 2/16 | 0/1 |
Safety Set included all randomized participants who received at least 1 dose of study medication, and had at least one post-dose safety assessment (within Period 2). Participants were classified into groups based on actual treatment received.
| Age, Continuous(years) | Setmelanotide 0.5 mg | Setmelanotide 1.5 mg | Setmelanotide 2.5 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 21.3 ± 4.19 | 24.1 ± 5.42 | 25.0 ± 9.62 | 30.5 ± 11.97 | 26.4 ± 9.47 |
| Sex: Female, Male(Participants) | Setmelanotide 0.5 mg | Setmelanotide 1.5 mg | Setmelanotide 2.5 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 2 | 6 | 6 | 7 | 21 |
| Male | 2 | 7 | 2 | 8 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Setmelanotide 0.5 mg | Setmelanotide 1.5 mg | Setmelanotide 2.5 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 1 | 1 | 4 |
| Not Hispanic or Latino | 2 | 13 | 7 | 14 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Setmelanotide 0.5 mg | Setmelanotide 1.5 mg | Setmelanotide 2.5 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 3 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 1 |
| White | 4 | 9 | 8 | 15 | 36 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2015 to primary completion in Oct 2016, 19 months.
Results were first posted in Jul 2023, 6 years 9 months after primary completion. A results delay was requested in Jan 2018.
Of 11 phase 2 interventional studies under Prader-Willi Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 27. This study's 19 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Setmelanotide
Rhythm Pharmaceuticals, Inc. →